NeuroVive completes enrollment in KL1333 clinical trial for mitochondrial disease
KL1333 clinical trial : Swedish biotech company NeuroVive Pharmaceutical has wrapped up recruitment of healthy volunteers in the second part of its ongoing phase Ia/b clinical trial for its drug candidate drug KL1333 for the chronic oral treatment of primary mitochondrial disease. According to NeuroVive Pharmaceutical, the first part of the clinical study assessed the […]